Drugs / GlucagonLikePeptide-1 (9-36)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02333591 Comparator | Jul 2016 → Jun 2018 | coronary microvascular disorder | Mette Zander | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GlucagonLikePeptide-1 (9-36) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02333591 ↗ |
| Route | Intravenous | “Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.” NCT02333591 ↗ |